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Abstract
Background: Pulmonary rehabilitation (PR) has demonstrated patients’ physiological and psychosocial
improvements, symptoms reduction and health-economic benefits whilst enhances the ability of the whole family
to adjust to illness. However, PR remains highly inaccessible due to lack of awareness of its benefits, poor referral
and availability mostly in hospitals. Novel models of PR delivery are needed to enhance its implementation while
maintaining cost-efficiency. We aim to implement an innovative community-based PR programme and assess its
cost-benefit.
Methods: A 12-week community-based PR will be implemented in primary healthcare centres where programmes
are not available. Healthcare professionals will be trained. 73 patients with CRD and their caregivers (dyads patient-
caregivers) will compose the experimental group. The control group will include dyads age- and disease-matched
willing to collaborate in data collection but not in PR. Patients/family-centred outcomes will be dyspnoea (modified
Medical Research Council Questionnaire), fatigue (Checklist of individual strength and Functional assessment of
chronic illness therapy – fatigue), cough and sputum (Leicester cough questionnaire and Cough and sputum
assessment questionnaire), impact of the disease (COPD Assessment Test), emotional state (The Hospital Anxiety
and Depression Scale), number of exacerbations, healthcare utilisation, health-related quality of life and family
adaptability/cohesion (Family Adaptation and Cohesion Scale). Other clinical outcomes will be peripheral (biceps
and quadriceps-hand held dynamometer, 1 or 10 repetition-maximum) and respiratory (maximal inspiratory and
expiratory pressures) muscle strength, muscle thickness and cross sectional area (biceps brachialis, rectus femoris
and diaphragm-ultrasound imaging), exercise capacity (six-minute walk test and one-minute sit to stand test),
balance (brief-balance evaluation systems test) and physical activity (accelerometer). Data will be collected at
baseline, at 12 weeks, at 3- and 6-months post-PR.
Changes in the outcome measures will be compared between groups, after multivariate adjustment for possible
confounders, and effect sizes will be calculated. A cost-benefit analysis will be conducted.
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Discussion: This study will enhance patients access to PR, by training healthcare professionals in the local primary
healthcare centres to conduct such programmes and actively involving caregivers. The cost-benefit analysis of this
intervention will provide an evidence-based insight into the economic benefit of community-based PR in chronic
respiratory diseases.
Trial registration: The trial was registered in the ClinicalTrials.gov U.S. National Library of Medicine, on 10th
January, 2019 (registration number: NCT03799666).
Keywords: Exercise training, Education and psychosocial support, Chronic respiratory diseases, Primary healthcare,
Cost-benefit,
Background
Respiratory diseases represent five of the thirty most
common causes of death worldwide [1, 2] and account
for more than 10% of all disability-adjusted life-years [1].
It is known that these conditions impact on economic
and social systems [3] but most importantly, cause enor-
mous challenges for individuals and respective families.
These patients experience disabling symptoms (includ-
ing dyspnoea, fatigue, cough, sputum, anxiety and de-
pression), limitation in their activities of daily life and
social/family interactions, exercise intolerance, low phys-
ical activity levels and impairments in their quality of life
[4–19]. Caregivers provide invaluable support to these
patients, i.e., emotional/spiritual (e.g., someone to whom
they can talk to), physical/practical (e.g., dressing, mobil-
ity assistance, medication check, overnight vigilance)
and social and financial [20, 21]. Although they report
positive experiences, negative impacts and specific needs
directly related to their role have also been widely ac-
knowledged [20–25]. However, very little has been done
to support caregivers and there is lack of interventional
studies [20, 21]. Pulmonary rehabilitation (PR) has been
proposed as a possible response [21, 23, 26] since it
could actively involve the family system within care de-
livery [27].
PR is a comprehensive intervention, which includes
exercise training, education and behaviour change, to
improve patients’ physical and psychological wellbeing
and to promote their long-term adherence to health-
enhancing behaviours [28]. In patients with chronic re-
spiratory diseases (CRD) (chronic obstructive pulmonary
disease [COPD], interstitial lung disease, bronchiectasis,
cystic fibrosis, asthma, pulmonary hypertension, lung
cancer), PR has demonstrated physiological and psycho-
social improvements, symptoms reduction and health
economic benefits [10, 29–37]. It has also shown to en-
hance the ability of the whole family to cope and psy-
chosocially adjust to illness [27]. Given its benefits, PR
has been proposed to be part of the standard care of-
fered to patients with CRD [10, 28]. However, it con-
tinues to be highly inaccessible [10]. Patients lack
awareness of its benefits, there is poor referral from
healthcare professionals and programmes are mostly
hospital-based and directed at patients with COPD at
advanced stages [28, 38]. Therefore, it has been acknowl-
edged that several steps are needed to increase access to
PR, such as: i) enhancing accessibility of the existing
programmes; ii) increasing the number of programmes
especially in the community; iii) developing and validat-
ing novel models to deliver sustainable PR; iv) increasing
PR reimbursement and payer acceptance; v) exploring
its cost-benefit; vi) promoting maintenance of long-term
results and vii) identifying those who should be priori-
tised [28, 38]. This study will address some of these
steps. It is hypothesised that community-based PR, di-
rected to patients with several CRD, at all grades of the
disease, and involving different local stakeholders (i.e.,
healthcare professionals, patients, caregivers, decision-
makers and the local community) may turn PR more ac-
cessible, sustainable and cost-effective.
Methods
Aims
The main goal of this project is to implement an innova-
tive community-based PR programme and assess its
cost-benefit. The primary objectives are to:
1.1.Investigate the short- and medium-term effects of
community-based PR programmes, implemented
with minimal resources and with local healthcare
professionals, in patients and caregiver’s health-
related quality of life;
1.2.Investigate the cost-benefit of the community-based
PR programmes on acute exacerbations and health-
care utilisation, to determine whether the intrinsic
perceived social value of such programmes have
identifiable benefits and, consequently, measurable
economic value for society.
The following secondary objectives will be addressed:
2.1 To explore the short- and medium-term effects of
community-based PR programmes on patients and
caregivers’ symptoms, impact of the disease, family
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adaptability/cohesion, peripheral and respiratory
muscle strength, exercise capacity, balance and
physical activity.
2.2 To explore differences between patients and
caregivers’ who participate and those who did not
participate in community-based PR programmes in
relation to dyspnoea, fatigue, cough, impact of the
disease, emotional state, health-related quality of
life, number of exacerbations, healthcare utilization,
family adaptability/cohesion, peripheral and respira-
tory muscle strength and thickness, exercise cap-
acity, balance and physical activity.
2.3 To explore associations between patients and
caregivers’ outcomes of dyspnoea, fatigue, cough,
impact of the disease, emotional state, number of
exacerbations, healthcare utilisation, family
adaptability/cohesion, peripheral and respiratory
muscle strength and thickness, exercise capacity,
balance and physical activity, pre-post community-
based PR programmes.
2.4 To investigate the short-term effects of community-
based PR programmes on patients’ peripheral
muscle (quadriceps and biceps) and diaphragm
thickness, cross sectional area, echointensity and
motion measured resorting to ultrasound imaging.
Study design, setting and recruitment
A real-world non-randomised controlled study con-
ducted in the community has been designed. Coordina-
tors of primary healthcare centres will be approached in
an arranged meeting to explain the study and those in-
terested to participate will be asked to identify the multi-
disciplinary team available in their primary healthcare
centre. Indication for the minimum staff required will be
provided, i.e., a physician, a physiotherapist and a nurse;
however, emphasis on the importance to include other
professionals (e.g., nutritionist, psychologist, social
worker), if available, will be given, following the inter-
national recommendations [28, 39, 40]. General practi-
tioners and/or pulmonologists will identify eligible stable
patients with a CRD (e.g., COPD, asthma, asthma-
COPD overlap, interstitial lung disease, etc.) and their
caregivers, and explain the study. Only patients and
caregivers with interest in participating will be contacted
by the researchers. A meeting will then be arranged to
provide written and oral information about the study
and collect the informed consent (Additional file 1). The
researchers also explained that all data would be kept in
databases password protected, using codes and their
names would never be disclosed, ensuring the confiden-
tiality and anonymity of all data. Two groups will be
composed, experimental (EG) and control (CG). The EG
will include patients and caregivers wanting to partici-
pate in a 12-week community-based PR programme and
the CG will include those age- and disease-matched will-
ing to collaborate in data collection but not in the PR
programme. Recruitment started in January 2019, with
final data collection expected to be completed in De-
cember 2019.
Patient and public involvement
Patients and public were not directly involved in the
study design or recruitment in this study however, au-
thors were informed about their needs, preferences and
expectations, as well as on the outcomes by recent pub-
lished papers of the research team, and took those into
consideration when designing the study [41, 42].
Eligibility criteria
Patients will be eligible if they are diagnosed with a CRD
[43, 44] and clinically stable in the previous month (i.e.,
no hospital admissions, exacerbations or changes in
medication for the cardiorespiratory system). Exclusion
criteria will be the presence of any clinical condition that
can preclude participants of being involved in the
community-based PR programme, such as, signs of cog-
nitive impairment (e.g. dementia) or presence of a sig-
nificant cardiovascular (e.g. symptomatic ischaemic
cardiac disease), neurological (e.g. neuromuscular dys-
trophy disease) or musculoskeletal disease (e.g. import-
ant kyphoscoliosis). Caregivers will be included if they
are: ≥18 years old and living with or providing physical/
supportive care to the patient, and excluded if they are
unable to cooperate.
Data collection
Sociodemographic (age, sex, educational level, marital
and working status), anthropometric (height and weight
to calculate the body mass index) and general clinical
data (long-term oxygen, non-invasive ventilation, med-
ical history, comorbidities to calculate the Charlson Co-
morbidity Index [45] and medication) will first be
collected with a structured questionnaire to characterise
the sample and will be followed by a lung function test
with spirometry [46].
The primary outcome measure will be health-related
quality of life, assessed with the St. George Respiratory
Questionnaire (SGRQ) [47] in patients and with the
World Health Organization Quality of Life Bref Ques-
tionnaire [48, 49] in caregivers. The number of acute ex-
acerbations, healthcare utilisation costs and collateral
costs (e.g. transport costs, work absence costs, sickness
benefits) will also be collected to conduct the cost-
benefit analysis [50].
In addition, the following secondary outcomes will be
assessed: symptoms of dyspnoea (modified Medical Re-
search Council Questionnaire [mMRC]) [51], fatigue
(Checklist of individual strength [CIS-20]) [52] and
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Functional assessment of chronic illness therapy – fa-
tigue [FACIT-F]) [53, 54], cough and sputum (Leicester
cough questionnaire [LCQ] [55] and Cough and sputum
assessment questionnaire [CASA-Q]) [56], impact of the
disease (COPD Assessment Test [CAT]) [57, 58], emo-
tional status (The Hospital Anxiety and Depression Scale
[HADS]) [59, 60], Family Adaptation and Cohesion
Scales [FACES-IV]) [61, 62], peripheral (biceps and
quadriceps with the hand held dynamometer, 1 [1-RM]
or 10 [10-RM] repetition-maximum) [63, 64] and in-
spiratory and expiratory muscle strength (respiratory
pressure meter) [65], exercise capacity (six-minute walk
test [6MWT] and one-minute sit to stand test [1-min
STS]) [66, 67], balance (brief-balance evaluation systems
test [Brief-BESTest]) [68] and physical activity (acceler-
ometer) [14]. Peripheral muscle (rectus femoris and bi-
ceps brachialli) and diaphragm thickness, cross sectional
area [69, 70] and echointensity [71], excursion and M-
Mode Index of Obstruction (MIO) [72–74], will be mea-
sured with ultrasound images – ImageJ and Matlab soft-
ware. Global rating of change scale [75] for fatigue,
cough, sputum, peripheral and respiratory muscle
strength and balance will also be collected.
Data will be collected from patients and caregivers
at baseline, at 12 weeks and at 3- and 6-months post-
PR. Ultrasound imaging will only be collected at base-
line and at 12 weeks in patients from the experimen-
tal group. Additional file 2 provides an overview of
enrolment, intervention and outcomes to be assessed
in each time point.
Intervention
A 12-week community-based PR programme will be im-
plemented in primary healthcare centre with minimal
resources (i.e., pulse oximeters, blood pressure monitors,
modified Borg scales, chairs, stairs, corridors, free
weights built with bottles with sand when others are not
available, elastic bands and cushions). Healthcare profes-
sionals from each primary healthcare centres will receive
two sessions of training, of three to 4 hours each, prior
to starting the programme. These sessions will focus on
how to assess patients’ comprehensively, main modules
to approach in the education and psychosocial compo-
nents and importance of involving a multidisciplinary
team. Physiotherapists will also revise principles of exer-
cise safety, prescription and patients’ monitoring. The
PR programme will then be implemented in collabor-
ation with members of the research team, who are highly
experienced professionals in running PR. When the pro-
grammes finish, local healthcare professionals will con-
tinue to implement programmes by themselves and the
research team will be available for assistance and clarifi-
cation of doubts by phone.
The programme will be composed of pre/post PR
comprehensive assessment of patients and caregivers,
two weekly sessions of exercise training and one session
of education and psychosocial support every other week.
Caregivers of the EG will be invited to participate in
these sessions that will be delivered in group, but perso-
nalised to each patient/caregiver.
Each exercise session will last between 60 and 75 min
and will be delivered by an experienced physiotherapist
in accordance with the international guidelines [28], i.e.,
it will include warm up, aerobic, resistance and balance
training and a cool down period. Furthermore, inspira-
tory muscle training [65] will be provided if maximal in-
spiratory pressure is < 80 cmH2O [76]. Heart rate and
oxygen saturation (with a pulse oximeter) and perceived
dyspnoea and fatigue (with the modified Borg scale)
[77], will be monitored throughout the sessions. Inten-
sity of the aerobic and resistance training will be indi-
vidually prescribed using the 6MWT [66] and the 1-RM
or 10-RM methods [64] (considering the availability of
the local equipment), respectively. After a 5 min. Warm-
up period (range-of-motion, stretching, low-intensity
aerobic exercises and breathing techniques), aerobic
training will be conducted in corridors and stairs/steps
or in cycloergometers or treadmills if available in the fa-
cilities, for 20–30 min at 80% of the average speed
achieved during the 6-MWT, or 60 to 80% of their work
peak, or 60 to 80% of maximum heart rate [40, 78]. Re-
sistance training will consist of 8 exercises of the major
upper and lower limb muscle groups, at 60 to 70% of 1-
RM or tailored in accordance to the 10-RM, using free
weights and ankle weights for 20–25 min [79]. A balance
training component will follow for 10min with exercises
for the six subsystems of balance control [80] and then
the programme will finish with a 5 min. Cool down
period. During the PR programme, progression in the
training intensity will be tailored according to the per-
ceived dyspnoea and fatigue (4–6 in the modified Borg
scale). A detailed description of the exercise training
component can be found in Fig. 1.
Each education and psychosocial session will last ap-
proximately 90 min. Six sessions will be conducted by a
multidisciplinary team. Based on the literature and pre-
vious experience, it is anticipated that some themes will
need to be addressed [42, 81–84] however, the compo-
nent will be tailored to patients and caregivers’ needs. A
detailed description of these sessions can be found in
Fig. 2.
Patients will also receive recommendations for home
training to complete on the additional days: i) aerobic,
resistance and balance exercises and general health
counselling to perform ⩾30min of moderate physical ac-
tivity ⩾5 days per week [85]. A leaflet with some exercise
options and physical activity guidance will be provided
Marques et al. BMC Public Health          (2019) 19:676 Page 4 of 11
Fig. 1 Community-based pulmonary rehabilitation – exercise training component. 6MWT – 6-min walk test; Wpeak - work peak; HRmax –
maximum heart rate; 1-RM – 1 repetition maximum; 10-RM – 10 repetition maximum; N/A – not applicable. Consent from participants was
obtained to publish the data
Fig. 2 Community-based pulmonary rehabilitation – education and psychosocial component
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(Fig. 3). Moreover, they will sign a physical activity con-
tract, which consists of encouraging self-efficacy and es-
tablishing individualised goal setting [86]. For this
purpose, the final goal of steps average count will be ne-
gotiated with the patients, accordingly to their baseline,
i.e., those with > 9000 steps/day - maintain or increase
steps/day; those with ≥6000 and < 9000 steps/day - reach
9000 steps/day and in those with < 6000 steps - increase
3000 steps/day by the end of the programme [87]. Fur-
thermore, the physiotherapist will provide weekly-
feedback to encourage patients to increase 562 steps
every week [88]. Participants will receive a pedometer
and a physical activity diary, to register their daily steps.
The CG will continue to receive the standard care
from the primary healthcare team.
Sample size
A sample size estimation with 80% power at 5% signifi-
cance was calculated to detect significant differences in
patients’ health-related quality of life assessed with the
SGRQ. The pre-post score achieved in the intervention
group of a PR in COPD integrating family-based educa-
tion and psychosocial support was used (Pre 37.9 ± 18.2
vs. Post 31.4 ± 18.7, p < 0.001) [27], resulting in a total
sample size of 73 participants. In PR programmes, drop-
out rates are approximately 20 to 40% [89, 90].
Therefore, 102 participants will be recruited. Sample size
calculation was performed using G*Power 3.1.3 (Univer-
sität Düsseldorf, Düsseldorf, Germany).
Data management and statistical analysis
All variables will be processed in IBM SPSS or MS Excel
software. Descriptive statistics, including frequencies,
means and standard deviations, medians and interquar-
tile ranges, will be used as appropriate. Short- and
medium-term effects of the community-based PR pro-
grammes will be verified using paired t-test or Wilcoxon
signed-rank tests, accordingly to data normality. Mean
scores of continuous variables will be compared between
patients and their caregivers using independent samples
t-test or Mann Whitney U test, depending on the vari-
able distribution. Pearson correlation coefficient [91]
and Bland and Altman plots [92] for continuous vari-
ables and Cohen’s k [93] for categorical variables, will be
applied to study the relationship and agreement between
patients and caregivers. Relationships between variables
will be explored with inferential, correlational and uni-
variate/multivariate analyses in SPSS. Differences be-
tween the EG and CG at different time points will be
assessed using a two-way ANOVA with repeated mea-
sures (continuous data), Kruskal-Wallis (ordinal data)
and Chi-square or Fisher exact probability tests (nominal
Fig. 3 Exercise options and physical activity recommendations for patients to perform at home
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data). If missing data is found during the study follow
up, the generalized estimating equation’ models will be
applied. This method is an extension of generalized lin-
ear models to longitudinal data which permits the inclu-
sion of time-dependent variables and the analysis of
incomplete data (without imputing missing data), com-
mon in longitudinal health studies [94]. A significance
level of 0.05 will be used.
Whenever possible, minimal clinically important dif-
ferences (MCID) will be established, following the
current recommendations to integrate both anchor-
based and distribution-based approaches [95, 96]. The
final MCID for each measure will be pooled using
MetaXL 5.3 (EpiGear International, Queensland,
Australia), with the input data being the MCID gener-
ated by each anchor- and distribution-based method
and, when appropriate, the respective confidence inter-
val. A quality effects model [97] will be used and
anchor-based methods will weigh more than distribution
methods (i.e., 2/3 against 1/3) [98].
A cost-benefit analysis will be conducted to determine
the economic value of the perceived social value of
community-based PR programmes. This analysis allows
for the aggregation of both health and non-health bene-
fits and costs of the PR programme and provides useful
and quantifiable information [99, 100], not only for pa-
tients and health care institutions, but also for decision
makers [101].
Focusing on the frequency and length of exacerba-
tions, healthcare utilisation costs and quality of life
gains, along with several indirect costs and benefits asso-
ciated with PR implementation, including productivity
loss of patients and caregivers who provide assistance,
working, transportation costs, administrative costs, op-
portunity costs, sickness benefits payed to the patient or
professional training and recruiting costs, three comple-
mentary data analysis will be held: cost:-effectiveness,
−utility and -benefit.
As recent studies on COPD have demonstrated, it is
suitable for cost-effectiveness analysis to rest on the ratio
incremental cost per exacerbation/healthcare utilisation
avoidance [102] aiming to compare relative costs and
outcomes of PR. Then, to assess the expected impact on
patients’ health-related quality of life, cost-utility analysis
computes the measures of quality adjusted life years
(QALY) [103] and healthy years equivalents (HYEs)
[104] and determines the incremental cost per QALY/
HYE gained. Finally, to account for the monetary trans-
lation of positive and negative effects of community-
based PR programmes, cost-benefit analysis will be per-
formed by determining the measures of net present
monetary benefit and economic internal rate of return
[105], along with a sensitivity analysis to control for the
uncertainty on the assessment of costs and benefits
associated to the community-based PR programmes
[106, 107].
Discussion
This real-world study will focus on enhancing patients’
access to PR by implementing it within their community,
with the staff available in local primary healthcare cen-
tres and actively involving informal caregivers. It will
also compute a measure of cost-benefit of implementing
this intervention in the community. This information is
needed for advocating the wide dissemination of PR
across the world, actively involve and train caregivers
and more healthcare professionals in the disease man-
agement of patients with CRD.
This study differs from others, by implementing a fun-
damental intervention for all patients with CRD, at dif-
ferent development stage of their disease, within the
community, near their homes and where it is known that
this intervention is lacking [38]. Patients with chronic
respiratory conditions have been accessing to PR mainly
in hospitals where constrains regarding availability,
transportation, funding and referral exist [28, 38, 108].
Although community-based PR in patients with COPD
has been found to be effective for health-related quality
of life [35, 36] and exercise capacity [36], caution inter-
preting these results is needed as relatively few studies
exist and they were conducted in several settings (home,
primary healthcare centres, a mixture of more than one
setting) with disparities in the structure and components
of the intervention, hindering strong conclusions regard-
ing the effects of community-based PR. In other CRD,
comparisons across settings are not even possible due to
the lack of studies [29, 30, 33]. Recently, a community-
based PR programme conducted in a non-healthcare fa-
cility with patients with several CRD demonstrated posi-
tive effects on patients’ exercise capacity, health-related
quality of life, and a reduction in respiratory-related hos-
pital admissions in the 12 months following the
programme [108]. However, primary healthcare centres
are embedded within the community, have a multidis-
ciplinary team available and most patients and their fam-
ilies have their routine follow-ups in these facilities.
Therefore, these community healthcare infrastructures
might be ideal candidates to enhance patients’ access to
PR but, staff often lacks training and equipment is
scarce. This study proposes to deliver a highly structured
training to available primary healthcare staff where PR is
non-existent, supervise the staff during one programme
delivery, using minimal resources, and guide them on
the development or acquisition of equipment. This will
increase the PR response to patients with chronic re-
spiratory conditions but, will also raise awareness in
more healthcare professionals for this intervention. It is
also known that caregivers are the main providers of
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support to these patients [20, 21] and it has been demon-
strated that when they are integrated in PR programmes
the whole family benefits from it [27]. Therefore, this pro-
ject will be innovative by empowering healthcare profes-
sionals of health facilities where PR programmes are not
available, but also by actively involving caregivers in this
intervention which together is believed to improve dis-
semination and sustainability of PR in the community di-
rected to patients with several CRD.
In addition, positive effects are expected to arise from
the cost-benefit analysis. The need to increase awareness
and knowledge of PR among rulers and decision makers
has been widely identified, and an economic evaluation
might be able to provide “value-for money” information
and promote the dialogue among different stakeholders
and consequently wider dissemination of PR pro-
grammes [10, 38].
Moreover, the longitudinal design will facilitate ana-
lysis of changes over time in a comprehensive set of
measures enhancing our knowledge on patients’ evolu-
tion. This will also represent the ideal opportunity to ex-
plore a wide range of emergent ultrasound measures to
assess the short-term effects of PR on the structure and
motion of the diaphragm and peripheral muscles (biceps
and quadriceps). Ultrasonographic assessment of the
rectus femoris muscle (thickness and cross sectional
area) has been found to be correlated with muscle
strength [70], and some measures of diaphragmatic kin-
etics have been proposed as promising to study disease
progression (e.g., MIO) [73, 74] and prognosis of PR
outcomes (e.g. change in the diaphragmatic length of
zone of apposition at functional residual capacity
ΔLzapp%) [109]. Nevertheless, relatively little is yet
known about the potential of the ultrasonographic as-
sessment to assess the effects of PR on peripheral
muscle (rectus femoris, biceps brachialis) and diaphragm
thickness, cross sectional area [69, 70] and echointensity
[71], excursion and MIO [72–74].
It is important to acknowledge the limitations of this
study. Although it is intended to implement a real-world
study as inclusive as possible and, therefore patients with
distinct CRD will be eligible, this might poses challenges
during the recruitment and implementation phases. This
limitation will be minimised by clarifying and emphasis-
ing the inclusion criteria in the meetings with healthcare
teams when explaining the study. Additionally, an expe-
rienced member in implementing PR programmes will
be present in all sessions together with the staff of the
primary healthcare centre to help with the personalised
interventions. The inclusion of chronic respiratory pa-
tients may also underpower the study. To mitigate this
risk, power calculations were based only on patients
with COPD, since they are the most common population
referred to PR programmes. Nevertheless, it will be
possible to use data from this study to compute power
calculations for other studies.
Another anticipated limitation is the recruitment of
caregivers. Caregivers are rarely included in PR pro-
grammes therefore, they might not be aware of the pos-
sible response that PR can provide not only to patients
but for the whole family. The importance of their inclu-
sion will be discussed with patients and caregivers when
explaining the study. A written information sheet
highlighting the importance of their inclusion will be
provided to promote their inclusion.
Moreover, acknowledging the benefits that PR has for
patients with CRD, not offering PR to all eligible patients
will never be considered. Therefore, the CG will be com-
posed of only those patients who are willing to partici-
pate in data collection but do not want take part in the
PR programme. This might lead to difficulties in recruit-
ing for the CG. Nevertheless, with the permission of pa-
tients and caregivers, a telephone call will be made prior
to data collection to minimise dropouts.
A follow-up period of 6 months could be too short to
draw conclusions about the medium- or long-term
changes in patients’ health and non-health measures, ne-
cessary for cost-benefit analysis. However, limited fund-
ing is available for the study.
Finally, obtaining cooperation of patients during the
ultrasound measurements of the diaphragm might be
challenging as these patients often present significant
dyspnoea and fatigue levels, limiting their collaboration
in the requested breathing manoeuvres.
We expect that this study will enhance the patients’
access to PR and provide an evidence-based insight into
the economic benefit of community-based PR in chronic
respiratory diseases, through a cost-benefit analysis.
Additional files
Additional file 1: Participants’ informed consent. Free informed consent
given to patients prior to integrate the study. (ZIP 2147 kb)
Additional file 2: 3R protocol schedule of enrolment, interventions and
outcomes (adapted from original table1). A table with an overview of
enrolment, intervention and outcomes to be assessed in each time point
in the study. (DOCX 23 kb)
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